Observational study finds clinical factors influence mechanical thrombectomy outcomes in young patients, suggesting risk management is vital.
Background and aims Ischemic stroke incidence is increasing among younger populations, with mechanical thrombectomy emerging as a crucial intervention for large vessel occlusions. This study examined the sociodemographic factors, clinical outcomes, and recovery trajectories in young patients to optimize and improve treatment protocols and strategies for this vulnerable demographic. Methods This observational study included young patients aged 18–55 years with ischemic stroke due to large vessel occlusion who underwent mechanical thrombectomy (MT) at a comprehensive stroke center in a tertiary hospital in Saudi Arabia. Data on demographics, clinical presentation, treatment protocols, and outcomes were collected and analyzed using IBM SPSS 29.0.0 Results Our study included 181 young patients with ischemic stroke (mean ± standard deviation age: 43.8 ± 10.0 years) who underwent MT. The most common stroke etiologies were large artery atherosclerosis (38.1%) and cardioembolism (27.6%). Revascularization success, defined as a modified Thrombolysis in Cerebral Infarction (mTICI) of 2b–3, was achieved in 92.8% of cases, with mTICI 3 (38.7%) being the most frequent outcome. Good functional outcomes, defined as a modified Rankin Scale score of 0–2 at 90 days, were observed in 62.4% of patients. Poor outcomes were significantly associated with higher low-density lipoprotein (p = 0.035), higher random blood sugar (p = 0.021), and elevated systolic blood pressure (p = 0.046). Recurrent stroke was a strong predictor of poor outcomes (p = 0.013). Conclusions Young Large Vessel Occlusion stroke outcomes after MT were influenced by sociodemographics, risk profiles, and clinical factors; early risk-factor management may optimize treatment strategies and outcomes. Conflict of interest Adi A. Aldubaiyan: nothing to disclose, Abdulmalik Alshoshan: nothing to disclose, Mohammed S. Alqahtani: nothing to disclose, Abdulrahman Alolyyan: nothing to disclose, Mohammed Alqurishi: nothing to disclose, Abdulrahman Alreshaid: nothing to disclose, Mohammed Alzawahmah: nothing to disclose, ABDELLAH DOUIRI: nothing to disclose, Anas Alrohimi: nothing to disclose, Ammar Alkawi: nothing to disclose, Fahad Alajlan: nothing to disclose, Ashfaq Shuaib: nothing to disclose, Adel Alhazzani: nothing to disclose
No takes yet. Share an insight, caveat, or question.
Aldubaiyan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: